[Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G ASCO 国产创新药表现亮眼 [Table_ReportDate] 2025 年 06 月 03 日 [Table_ReportType] 医药生物行业周报（5 月第 5 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（5 月 26 日-5 月 30 日）医药生物板 块收涨 2.21%，跑赢 wind 全 A（-0.02%）和沪深 300 （-1.08%）。从板块来看，其他生物制品（4.65%）、化 学制剂（4.27%）和医疗研发外包（4.0%）涨幅居前， 线下药店（-2.69%）跌幅居前。从个股来看，舒泰神 （60.4%）、华森制药（42%）和常山药业（35.9%）涨 ...

Core Viewpoint - Waterdrop Inc., known for its crowdfunding platform "Waterdrop Fundraising," is facing growth challenges despite a slight revenue increase in 2024. The company's main business, insurance, shows limited growth potential, and its recent expansion into CRO (Contract Research Organization) services is also under pressure due to industry competition and regulatory challenges [2][6][23]. Group 1: Company Overview - Waterdrop Inc. is primarily an insurance company that uses its crowdfunding platform to drive traffic to its insurance services, which has been a key part of its business model [2][9]. - The company has experienced a decline in revenue from 30.71 billion RMB in 2021 to 23.41 billion RMB in 2023, with a slight recovery expected in 2024 [12]. - The insurance business has consistently accounted for over 85% of the company's total revenue from 2021 to 2024 [9]. Group 2: Financial Performance - The insurance-related revenue for Waterdrop Inc. was 30.71 billion RMB in 2021, 25.59 billion RMB in 2022, and 23.41 billion RMB in 2023, indicating a downward trend [12]. - Operating profit from the insurance segment has also declined from 10.35 billion RMB in 2021 to 4.77 billion RMB in 2024 [12]. - In 2024, the company reported a slight increase in overall revenue, but the growth was primarily driven by a reduction in losses from its crowdfunding business [14]. Group 3: CRO Business Development - Waterdrop Inc. expanded into the CRO business in 2022, which initially showed promise with a revenue increase of approximately 68% in 2023 [4][20]. - However, in 2024, the CRO business revenue declined by 9.4%, reflecting a challenging market environment and increased competition [4][21]. - The CRO segment's performance is under pressure due to tightening budgets from pharmaceutical companies and a competitive landscape dominated by established players [21][23]. Group 4: Challenges and Risks - The company's crowdfunding platform, Waterdrop Fundraising, has faced scrutiny due to issues with trust and transparency, impacting its ability to convert traffic into insurance sales [10][11]. - Recent controversies, including fraudulent fundraising cases, have led to a crisis of credibility for both the platform and the parent company [11]. - The increase in service fees for the crowdfunding platform may negatively affect donor trust and subsequently the conversion rates to insurance products [14][15].

行业投资评级 强于大市 |维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 7533.02 | | 52 周最高 | 8490.25 | | 52 周最低 | 6070.89 | 行业相对指数表现 2024-05 2024-08 2024-10 2024-12 2025-03 2025-05 -18% -14% -10% -6% -2% 2% 6% 10% 14% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 证券研究报告：医药生物|行业周报 发布时间：2025-05-26 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《特朗普计划降低美国药品价格，CXO 企业有望受益》 - 2025.05.19 医药生物行业报告 （2025.05.19-2025.05.25） 三生制药创出海交易新纪录，中国创新药企或迎 Lisence out 密集收获期 l 一周观点：三生制药重磅 ...

证券研究报告：医药生物|行业周报 发布时间：2025-05-26 行业投资评级 强于大市 |维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 7533.02 | | 52 周最高 | 8490.25 | | 52 周最低 | 6070.89 | 行业相对指数表现 2024-05 2024-08 2024-10 2024-12 2025-03 2025-05 -18% -14% -10% -6% -2% 2% 6% 10% 14% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《特朗普计划降低美国药品价格，CXO 企业有望受益》 - 2025.05.19 医药生物行业报告 （2025.05.19-2025.05.25） 三生制药创出海交易新纪录，中国创新药企或迎 Lisence out 密集收获期 l 一周观点：三生制药重磅 ...

中国通号：中标总计约37.89亿元轨道交通市场重要项目 5月23日晚，中国通号（688009）发布公告称，公司在2025年3月至4月共中标十一个轨道交通市场重要 项目，包括铁路市场8个和城市轨道交通市场3个。以上项目中标金额总计约为37.89亿元，约占该公司 中国会计准则下2024年经审计营业收入的11.67%。因为上述项目跨年分期实施，对2025年当期业绩影 响有不确定性。 资料显示，中国通号成立于2010年12月，主营业务是轨道交通控制系统及其衍生业务，同时开展轨道交 通配套工程施工业务、市政信息化及其配套工程总承包业务和海外轨道交通建设相关业务等。 所属行业：机械设备–轨交设备Ⅱ–轨交设备Ⅲ 新柴股份：拟使用不超过5亿元闲置资金购买理财产品 5月23日晚，新柴股份（301032）发布公告称，公司计划使用不超过5亿元的闲置自有资金购买安全性 高、流动性好、中低风险的结构性存款、收益凭证等理财产品。该计划旨在提高资金使用效率，增加现 金资产收益。 资料显示，新柴股份成立于2007年6月，主营业务是非道路用柴油发动机及相关零部件的研发、生产与 销售。 所属行业：机械设备–通用设备–其他通用设备 5月23日晚， ...

市场表现： 2025 年5 月22 日，医药板块涨跌幅-0.73%，跑输沪深300 指数0.67pct，涨跌幅居申万31 个子行业第14 名。各医药子行业中，医疗研发外包(+0.04%)、血液制品(-0.37%)、其他生物制品（-0.51%）表现居 前，医院（-1.83%)、线下药店(-1.65%)、医药流通（-1.37%)表现居后。个股方面，日涨幅榜前3 位分别 为三生国健(+20.00%)、亚虹医药(+12.26%)、迈威生物(+11.71%)；跌幅榜前3 位为赛升药业 （-11.63%）、拓新药业(-10.93%)、拱东医疗（-9.99%)。 行业要闻： 近日，Ionis 宣布，公司开发的反义寡核苷酸（ASO）疗法Tryngolza（Olezarsen）在Essence 临床3 期研 究中取得积极的顶线结果。数据显示，该药在治疗6 个月后显著降低了患者的甘油三酯水平，达到主要 终点，且在所有关键次要终点上也取得统计学显著改善。Olezarsen 是一种反义寡核苷酸疗法，旨在抑 制机体产生载脂蛋白C-III（apoC-III，一种在肝脏中产生的调节血液中TG 代谢的蛋白）。 风险提示：新药研发及上市不及预 ...

拐点已现，积极配置 ——CXO 2024&2025Q1业绩综述 行业评级：看好 2025年05月14日 | 分析师 | 郭双喜 | 王帅 | | --- | --- | --- | | 邮箱 | guoshuangxi@stocke.com.cn | wangshuai@stocke.com.cn | | 电话 | 19801116960 | 13548094491 | | 证书编号 | S1230521110002 | S1230523060003 | 1 1、股价复盘： 2、财务分析： ➢ 本土：业绩、订单&AI是主线。 2024.12.31至2025.04.30，医疗研发外包指数上涨0.82%，跑赢医药生物（申 万）指数0.64pct，其中药明生物（+31.55%） 、药明合联（+23.65%） 、泓博医药（+16.11%） 、凯莱英 （+7.77%）、药明康德（+7.50%）表现较好。 95% ➢ 海外：业绩分化，CDMO更强劲。2024.12.31至2025.04.30，Lonza及LABCORP领涨。从指引看跨国CXO公 司只有Lonza对CDMO业务（胶囊与健康原料CHI以外业务）2025年指引 ...

证券研究报告：医药生物|行业周报 发布时间：2025-05-19 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7401.23 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 | 周最低 | 6070.89 | 行业相对指数表现 2024-05 2024-07 2024-10 2024-12 2025-03 2025-05 -21% -17% -13% -9% -5% -1% 3% 7% 11% 15% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《医药 2024&2025Q1 总结——关注现 金流、盈利能力优先改善品种》 - 2025.05.15 医药生物行业报告 （2025.05.12-2025.05.18） 特朗普计划降低美国药品价格，CXO 企业有望受益 l 一周观点 ...

证 券 研 究 报 告 盈利能力复苏，拐点初现 医药生物行业2024年报暨25Q1季报总结 证券分析师：张静含 A0230522080004 研究支持：李敏杰 A0230523070006 2025.5.16 投资案件 www.swsresearch.com 证券研究报告 2 ◼ 整体业绩表现：2024年473家沪深两市A股医药上市公司实现营业总收入24,588亿元， 同比下降0.9%，实现归母净利润1,412亿元，同比下降12.1%。25Q1板块实现营业总 收入6,104亿元，同比下降4.2%，实现归母净利润487亿元，同比下降8.7%，去除 24Q1大额BD的基数扰动，25Q1板块归母净利润同比增长0.7%，净利润率也有 0.3%的提升，这是医药板块在经历了三年盈利能力下行后首次出现利润率反转的迹象。 ◼ 子板块及个股业绩亮点：一季度业绩表现较好的子板块包括CXO、创新药、生物制品、 民营医院、医疗耗材等。CXO板块从24Q4起业绩底部反转，创新药板块收入持续保持 高增长。同时值得注意的是，一季度有多家头部公司业绩超预期，如药明康德、恒瑞 医药、百济神州、爱尔眼科、华兰生物、甘李药业、益丰药房、大参林、云 ...

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]